CVI Holdings LLC Buys Shares of 596,372 INmune Bio, Inc. (NASDAQ:INMB)

CVI Holdings LLC bought a new position in shares of INmune Bio, Inc. (NASDAQ:INMB) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 596,372 shares of the company’s stock, valued at approximately $5,260,000. INmune Bio accounts for about 4.8% of CVI Holdings LLC’s holdings, making the stock its 4th largest position.

Several other large investors have also recently added to or reduced their stakes in the business. Marshall Wace LLP increased its stake in INmune Bio by 332.1% during the 2nd quarter. Marshall Wace LLP now owns 115,916 shares of the company’s stock worth $1,022,000 after buying an additional 89,091 shares during the period. Bank of New York Mellon Corp increased its stake in INmune Bio by 124.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 58,600 shares of the company’s stock worth $517,000 after buying an additional 32,511 shares during the period. Westside Investment Management Inc. increased its stake in INmune Bio by 31.8% during the 2nd quarter. Westside Investment Management Inc. now owns 45,340 shares of the company’s stock worth $400,000 after buying an additional 10,950 shares during the period. Fermata Advisors LLC increased its stake in INmune Bio by 8.5% during the 2nd quarter. Fermata Advisors LLC now owns 34,140 shares of the company’s stock worth $301,000 after buying an additional 2,689 shares during the period. Finally, Rhumbline Advisers purchased a new stake in INmune Bio during the 2nd quarter worth approximately $121,000. 12.72% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Raymond James assumed coverage on shares of INmune Bio in a research note on Friday. They set an “outperform” rating and a $18.00 target price on the stock. Scotiabank assumed coverage on shares of INmune Bio in a research report on Thursday, August 22nd. They issued a “sector outperform” rating and a $22.00 price objective on the stock.

INmune Bio Trading Up 5.2 %

Shares of NASDAQ:INMB opened at $5.22 on Friday. INmune Bio, Inc. has a 52 week low of $4.81 and a 52 week high of $14.74. The company’s 50 day moving average is $6.79 and its two-hundred day moving average is $8.83. The company has a market cap of $103.26 million, a PE ratio of -2.72 and a beta of 1.86.

INmune Bio (NASDAQ:INMB) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.50) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.13. INmune Bio had a negative net margin of 26,333.59% and a negative return on equity of 103.56%.

Insider Buying and Selling at INmune Bio

In related news, CFO David J. Moss bought 7,690 shares of the stock in a transaction dated Thursday, September 12th. The stock was acquired at an average price of $6.38 per share, for a total transaction of $49,062.20. Following the acquisition, the chief financial officer now owns 1,275,869 shares in the company, valued at approximately $8,140,044.22. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CEO Raymond Joseph Tesi bought 15,380 shares of the stock in a transaction dated Thursday, September 12th. The stock was acquired at an average price of $6.38 per share, for a total transaction of $98,124.40. Following the acquisition, the chief executive officer now owns 1,554,106 shares in the company, valued at approximately $9,915,196.28. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO David J. Moss bought 7,690 shares of the stock in a transaction dated Thursday, September 12th. The stock was bought at an average price of $6.38 per share, with a total value of $49,062.20. Following the acquisition, the chief financial officer now owns 1,275,869 shares in the company, valued at approximately $8,140,044.22. The disclosure for this purchase can be found here. Insiders own 35.20% of the company’s stock.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.